Boehringer Ingelheim Press Releases

Press Release Subscription: Signup here to the Boehringer Ingelheim Newsletter to receive press-releases via email.

Information for...

General Use Patients or Carers Health Care Professionals in the US Health Care Professionals outside the US and UK Journalists Jobseekers

PRESS RELEASE 07 Oct 2019 at 09:00

Winners of the 2019 European PRRS Research Award announced

Read more on Winners of the 2019 European PRRS Research Award announced
PRESS RELEASE 01 Oct 2019 at 09:00

Boehringer Ingelheim obtains EMA authorization for Reprocyc® ParvoFLEX, a new porcine parvovirus vaccine

Read more on Boehringer Ingelheim obtains EMA authorization for Reprocyc® ParvoFLEX, a new porcine parvovirus vaccine
PRESS RELEASE 30 Sep 2019 at 08:00

INBUILD® meets primary endpoint - study evaluated nintedanib in patients across a range of progressive fibrosing interstitial lung diseases1

Read more on INBUILD® meets primary endpoint - study evaluated nintedanib in patients across a range of progressive fibrosing interstitial lung diseases1
PRESS RELEASE 27 Sep 2019 at 08:30

New therapeutic indications for NexGard®, NexGard SPECTRA® and Broadline® approved by EMA

Read more on New therapeutic indications for NexGard®, NexGard SPECTRA® and Broadline® approved by EMA
PRESS RELEASE 26 Sep 2019 at 08:00

Boehringer Ingelheim donates vaccines to help fight rabies

Read more on Boehringer Ingelheim donates vaccines to help fight rabies
PRESS RELEASE 20 Sep 2019 at 14:00

Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases

Read more on Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases
PRESS RELEASE 20 Sep 2019 at 13:00

Boehringer Ingelheim breaks ground on its strategic vaccine production center for veterinary public health

Read more on Boehringer Ingelheim breaks ground on its strategic vaccine production center for veterinary public health
PRESS RELEASE 12 Sep 2019 at 09:00

Boehringer Ingelheim showcases its leading avian vaccines and services at WVPAC 2019

Read more on Boehringer Ingelheim showcases its leading avian vaccines and services at WVPAC 2019
PRESS RELEASE 04 Sep 2019 at 09:00

Boehringer Ingelheim Expands KRAS Cancer Program with Lupin’s Clinical Stage MEK Inhibitor Compound

Read more on Boehringer Ingelheim Expands KRAS Cancer Program with Lupin’s Clinical Stage MEK Inhibitor Compound
PRESS RELEASE 03 Sep 2019 at 08:00

Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity/Diabetes

Read more on Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity/Diabetes
PRESS RELEASE 26 Aug 2019 at 13:53

Change in the Board of Managing Directors at Boehringer Ingelheim

Read more on Change in the Board of Managing Directors at Boehringer Ingelheim
PRESS RELEASE 19 Aug 2019 at 10:00

Social entrepreneurs improve healthcare access across the African continent

Read more on Social entrepreneurs improve healthcare access across the African continent
PRESS RELEASE 13 Aug 2019 at 09:00

Boehringer Ingelheim opens Health Management Centre in China

Read more on Boehringer Ingelheim opens Health Management Centre in China
PRESS RELEASE 12 Aug 2019 at 15:00

Boehringer Ingelheim and MD Anderson form unique Virtual Research and Development Center to rapidly advance new cancer therapies

Read more on Boehringer Ingelheim and MD Anderson form unique Virtual Research and Development Center to rapidly advance new cancer therapies
PRESS RELEASE 02 Aug 2019 at 11:30

Updated real-world data shows Giotrif®/Gilotrif® (afatinib) followed by osimertinib provided a median overall survival of up to almost four years in patients with EGFR Del19 and T790M mutation-positive NSCLC

Read more on Updated real-world data shows Giotrif®/Gilotrif® (afatinib) followed by osimertinib provided a median overall survival of up to almost four years in patients with EGFR Del19 and T790M mutation-positive NSCLC
PRESS RELEASE 01 Aug 2019 at 10:00

First half 2019: High levels of investment in R&D and robust organic growth

Read more on First half 2019: High levels of investment in R&D and robust organic growth
PRESS RELEASE 18 Jul 2019 at 15:00

INMARK® results suggest prompt treatment of IPF with antifibrotics to slow disease progression

Read more on INMARK® results suggest prompt treatment of IPF with antifibrotics to slow disease progression
PRESS RELEASE 15 Jul 2019 at 14:00

Boehringer Ingelheim Acquires AMAL Therapeutics, Significantly Enriching Its Cancer Immunology Portfolio with Novel Cancer Vaccines Platform

Read more on Boehringer Ingelheim Acquires AMAL Therapeutics, Significantly Enriching Its Cancer Immunology Portfolio with Novel Cancer Vaccines Platform
PRESS RELEASE 08 Jul 2019 at 10:00

Speech recognition can detect warning signals for schizophrenia or Alzheimer's dementia

Read more on Speech recognition can detect warning signals for schizophrenia or Alzheimer's dementia
PRESS RELEASE 04 Jul 2019 at 08:30

FRONTLINE® becomes ‘Brand of the Year’ 2019-2020 in World Branding Awards

Read more on FRONTLINE® becomes ‘Brand of the Year’ 2019-2020 in World Branding Awards